We aim to confirm previous observations among postmenopausal osteoporotic women who received denosumab in terms of densitometric changes. We performed an observational clinical practice scenario study assessing baseline bone mineral density and its change after 2 years of treatment in postmenopausal osteoporotic women. Most of our patients were severe and had previous fracture and had received several treatments before denosumab initiation. We observed a 10.06% (± 3.46) improvement in spine, and a 4.87% (± 4.78) improvement in femoral neck. Our findings are in accordance with other authors that suggest denosumab provides densitometric gain in clinical practice in severe postmenopausal osteoporotic women.
Keywords: Bone mineral density; Denosumab; Osteoporosis.